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Abstract Colorectal cancer is one of the most common cancers worldwide, and
although associated mortality rates in South American countries are gener-
ally among the lowest in the world, they are on the rise.
The prognosis of patients diagnosed with metastatic colorectal cancer has
improved markedly over the last 12 years, increasing from 5months with best
supportive care to almost 2 years with combination chemotherapy plus bev-
acizumab. New prognostic and predictive biomarkers have been identified to
guide therapy. Prognostic markers indicate patient survival independent of
therapy and include disease stage, mutational status, and carcinoembryonic
antigen. More recently, predictive markers of treatment outcomes have been
identified. The most studied are mutations of the KRAS and BRAF genes,
which are associated with resistance to epidermal growth factor receptor-
targeted therapy.
Tumor blood vessels have a number of structural and functional abnor-
malities that result in increased tumor vascularity and growth driven by
angiogenesis. The anti-vascular endothelial growth factor (VEGF) mono-
clonal antibody bevacizumab, which binds to and neutralizes VEGF-A, has
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become a central part of the treatment of metastatic colorectal cancer. The
addition of bevacizumab to fluorouracil (5-FU)/leucovorin, irinotecan plus
bolus 5-FU/leucovorin, or irinotecan plus infusional 5-FU/leucovorin sig-
nificantly improves the overall survival of patients with previously untreated
metastatic colorectal cancer. In addition, a significant increase in overall
survival is seen when bevacizumab is added to oxaliplatin plus infusional
5-FU/leucovorin (FOLFOX) in patients with metastatic colorectal cancer
who progressed on a non-bevacizumab-containing regimen.
Although the majority of studies were performed prior to the identification
ofKRAS andBRAF as predictive biomarkers, subsequent analysis has shown
the benefits of bevacizumab occur independently of the mutational status of
these genes. In patients who have progressed on a bevacizumab-containing
regimen, continuation of bevacizumab is significantly associated with an
improved survival based on observational cohort studies. Surgical resection is
recommended in patients with metastatic colorectal cancer where complete
removal of tumors can be achieved. Perioperative chemotherapy using
FOLFOX for 3 months before and 3 months after surgery is associated with a
9% improvement in 3-year survival. The use of chemotherapy in patients
initially deemed unresectable has produced resection rates approaching 40%,
and the addition of bevacizumab to chemotherapy in this setting is feasible,
safe, and effective. In a study of 219 patients, the addition of bevacizumab to
FOLFOX was associated with a significant increase in major or complete
pathologic response compared with FOLFOX alone.
Improvements in patient survival have changed the treatment paradigm
for metastatic colorectal cancer. Newer approaches view treatment not as
distinct lines of therapy but as a continuum that includes personalized
treatment plans offering maintenance therapy and even drug holidays be-
tween aggressive treatment periods. This approach achieves similar efficacy
outcomes with reduced toxicity, and investigation of the role of bevacizumab
as maintenance therapy is ongoing.
1. Introduction
Worldwide, colorectal cancer is the fourth
most common neoplasm in men and the third
most common in women.[1] Although mortality
rates from the disease in South America remain
among the lowest in the world, a recent trend
towards increasing mortality due to colorectal
cancer has been seen inMexico, Brazil, Chile, and
Ecuador.[1] The majority of colorectal cancer
cases arise from an adenomatous polyp, which
progresses into advanced adenoma with high-
grade dysplasia, and finally transforms into in-
vasive cancer.[2] The appearance of polyps and
subsequent transformation into cancerous le-
sions may involve both genetic and environ-
mental factors. Colorectal cancer that is localized
within the colon or has only spread to the lymph
nodes is curable by surgery with or without che-
motherapy, and has a 5-year survival rate of
44–93%.[3] However, cancer that has metasta-
sized to distant sites is generally incurable and has
a 5-year survival rate of <10%.[3]
Twenty-five years ago, few physicians were
optimistic about the chances of progress in the
treatment of colorectal cancer and for improved
survival for patients with this disease. However,
over the last decade or so, survival rates of
patients with metastatic colorectal cancer have
increased from 5 months with best supportive
care[4] to almost 2 years with combination che-
motherapy with fluorouracil (5-FU), leucovorin
plus irinotecan plus bevacizumab (figure 1).[7]
Throughout this time, a growing body of evidence
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has developed to support the importance of vas-
cular and nutritional support for the survival of
the tumor, and has ultimately led to the devel-
opment of agents such as bevacizumab, which
work through disruption of tumor blood flow by
decreasing angiogenesis. This review is based on a
series of meetings of an opinion and analysis panel
in Mexico City in September 2009, and discusses
a number of important issues in the treatment of
colorectal cancer, including the use of prognostic
and predictive biomarkers, the optimum treat-
ment of metastatic disease, and resection of he-
patic metastases.
2. Predictive and Prognostic Biomarkers
in Colorectal Cancer
A number of prognostic and predictive in-
dicators are used to guide therapy in patients with
colorectal cancer, and the difference between the
two types of markers is an important distinction
to make. A prognostic marker is indicative of pa-
tient survival independent of treatment, whereas
a predictive marker is indicative of therapeutic
efficacy.
Colorectal cancer may arise from two distinct
mutational pathways. Approximately 15% of tu-
mors display microsatellite instability (MSI) mu-
tations, giving rise to a phenotype of tumors
termed high-frequency MSI (MSI-H).[11] How-
ever, the majority (~85%) of colorectal cancers
arise through chromosomal instability and have
genetic alterations involving loss of heterozygosity,
chromosomal amplifications, and chromosomal
translocations.[11] These tumors, termed micro-
satellite-stable (MSS) tumors, present and behave
in a similar way to low-frequency MSI (MSI-L)
tumors. Compared withMSS andMSI-L tumors,
MSI-H tumors are more frequently right-sided,
high-grade, and mucinous types.[11] They are also
likely to have a larger primary tumor at diagnosis,
but are more frequently node negative. Patients
with MSI-H tumors have a better long-term prog-
nosis compared with similarly staged MSS tumors.
MSI might be a predictive marker, as patients
with MSI-H colon cancers gain no benefit from
5-FU-based adjuvant chemotherapy.[12]
Elevated carcinoembryonic antigen (CEA)
prior to surgical resection is a poor prognostic
indicator; a serum level of 5 ng/mL is considered
a standard cut-off.[13] While in the past CEA
levels have been used in conjunction with over-
all stage to define a subset of patients in whom
































Fig. 1. Median overall survival following first-line treatment for metastatic colorectal cancer.[4-10] 5-FU = fluorouracil; BEV = bevacizumab;
FOLFIRI = irinotecan plus infusional fluorouracil/leucovorin; FOLFOX =oxaliplatin plus infusional fluorouracil/leucovorin; IFL = irinotecan plus
bolus fluorouracil/leucovorin; LV = leucovorin.
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guidelines recommend that CEA only be used to
indicate disease recurrence following resection.[14]
Abnormalities of the tumor suppressor gene p53,
situated on chromosome 17p, are associated with
the development of colorectal cancer, but the
current value of using p53 as a prognostic marker
in colorectal cancer is unclear.[11] For example, an
increased risk of mortality was seen with the
presence of p53 mutation in resected stage II and
III colon cancer in a retrospective review.[11]
However, expression of p53 was associated with
favorable survival in stage III but not stage II
disease in a study by the Southwest Oncology
Group.[15]
The RAS and RAF families of proteins act
as transducers and integrators of signals from a
number of surface growth factors with down-
stream effects on subsequent transducers, such as
PI3K and MAPK. Mutations of KRAS occur in
approximately 40% of colorectal cancer speci-
mens,[16] and although these mutations do not
appear to be a prognostic factor in colorectal
cancer, they do confer resistance to epidermal
growth factor receptor (EGFR)-targeted therapy.
For example, in the CRYSTAL trial (see table I
for full trial names), in which patients with me-
tastatic EGFR-expressing colorectal cancer re-
ceived irinotecan plus infusional 5-FU/leucovorin
(FOLFIRI) with or without cetuximab, the ben-
efit of the anti-EGFR monoclonal antibody was
confined to patients withoutKRASmutations.[17]
Based on these and other findings, the European
Medicines Agency approved the EGFR inhibitor
panitumumab for use in patients with wild-type
KRAS only.[18] BRAF mutations occur less fre-
quently, but are also associated with reduced
response to EGFR inhibitors. The BRAF-V600E
mutation, in particular, impairs the therapeutic
effects of cetuximab and panitumumab.[19] Con-
sensus guidelines recommend that the presence of
KRAS mutations be determined in all patients
diagnosed with stage IV colorectal cancer.[14]
There are currently no suitable predictive bio-
markers for bevacizumab treatment.[20-23]
It was originally thought that markers of tumor
angiogenesis could be used to predict clinical
outcome to bevacizumab therapy; however, vas-
cular endothelial growth factor (VEGF) expression
and microvessel density do not predict treatment
outcome in patients with colorectal cancer.[22] In
addition, thrombospondin expression within the
tumor does not predict response to bevacizumab.[22]
Angiopoietin-2 is a key regulator of VEGF
function,[24] andGoede et al.[25] investigated whether
angiopoietin-2 was a candidate biomarker for
predicting outcome in patients with metastatic
colorectal cancer treated with bevacizumab. Serum
angiopoietin-2 was significantly elevated in pa-
tients with metastatic colorectal cancer versus
healthy subjects. Patients with stage IV colorectal
cancer had significantly higher serum angiopoie-
tin-2 levels versus patients with stage I–III colo-
rectal cancer or healthy controls (3.9 vs 2.3ng/mL,
p = 0.001; and 3.9 vs 2.4 ng/mL, p= 0.006, re-
spectively). Low serum angiopoietin-2 levels were
associated with a significantly better response
rate (82% vs 31%; p < 0.01) compared with high
serum angiopoietin-2 levels in patients receiving
bevacizumab-based regimens. A prolonged median
progression-free survival (14.1 vs 8.5 months;
p < 0.01) and a 91% reduction in death (p < 0.05)
was also observed.[25]
In a phase II study examining the efficacy of
FOLFIRI plus bevacizumab in patients previ-
ously untreated for metastatic colorectal cancer,
elevated baseline interleukin-8 levels were asso-
ciated with a shorter median progression-free
survival (11 vs 15.1 months; p = 0.03).[26] Basic
fibroblast growth factor, placental growth factor,
and hepatic growth factor were all elevated be-
fore disease progression.[26]
Table I. Trial names
Acronym Trial name
BEAT Bevacizumab Expanded Access Trial
BICC-C Bolus, Infusional, or Capecitabine with Camptosar-
Celecoxib
BOND-2 Bowel Oncology with Cetuximab Antibody
BRiTE Bevacizumab Regimens: Investigation of Treatment
Effects and Safety
CAIRO Capecitabine, Irinotecan, and Oxaliplatin in Advanced
Colorectal Cancer
CRYSTAL Cetuximab Combined With Irinotecan in First-Line
Therapy for Metastatic Colorectal Cancer
OPTIMOX Optimized Leucovorin-Fluorouracil-Oxaliplatin
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Further investigation into the predictive molec-
ular markers for clinical outcome to bevacizumab
is required.
3. Angiogenesis andVascular Endothelial
Growth Factor
Blood vessels supplying tumors have a number
of abnormalities in their structure and func-
tion.[27] Like normal blood vessels, those in solid
tumors are composed of endothelial cells, mural
cells, and a basementmembrane.However, tumor
vessels exhibit abnormalities in each of the struc-
tural components.[27] In addition, they are irreg-
ularly shaped, poorly organized, and lack the
arteriole-capillary-venule hierarchy. The secretion
of certain factors alters the balance between en-
dothelial cell proliferation and apoptosis, result-
ing in increased cell division and stimulation of
the formation of new vessels through angio-
genesis.[28,29] Co-option of existing blood vessels
or incorporation of bone marrow progenitor cells
into existing vessels also increases tumor blood
supply.[30] Structural abnormalities of the endo-
thelial layer of tumor blood vessels reduce nor-
mal barrier function and make them prone to
leaking.[31] This increases interstitial fluid pres-
sure, compromising blood flow to the affected
area, and has implications for drug delivery to
the tumor.[32] Impaired barrier function also in-
creases the extravasation of tumor cells, and thus
metastasis and growth factors produced or re-
leased by blood monocytes/macrophages con-
tribute to tumor progression.[27,33] This impaired
endothelial function increases the risk of hemor-
rhage in the tumor and has implications for
patients undergoing surgery.[27]
VEGF is highly expressed on the endothelial
cells of blood vessels supplying tumors and pro-
motes the growth of endothelial cells in arteries,
veins, and lymphatic vessels.[34] In addition, it
stimulates angiogenesis in vivo,[35] promotes vas-
cular permeability and capillary leak,[36] and induces
the expression of molecules that control the adhe-
sion of leukocytes in models of inflammation.[37]
These effects occur through binding of VEGF
to VEGF receptor-2 (also known as Flk-1 or
KDR).[38] Bevacizumab is a humanized mono-
clonal antibody that binds to and neutralizes
VEGF-A. It has a half-life of approximately
17–21 days and does not elicit an antibody res-
ponse in clinical trials.[39] Bevacizumab has been
investigated for the treatment of a range of tumor
types and is an important factor in the treatment
of metastatic colorectal cancer.
4. Bevacizumab and Metastatic
Colorectal Cancer
Bevacizumab improves overall survival in pa-
tients with metastatic colorectal cancer when used
in conjunction with 5-FU-based chemotherapy
regimens. The majority of studies were conducted
prior to testing for the predictive markers dis-
cussed in section 2; however, subsequent analyses
show that benefit with bevacizumab occurs irre-
spective of KRAS, BRAF, or p53 status.[40] A
pooled analysis of phase II studies showed a me-
dian survival of 17.9 months in patients receiving
5-FU/leucovorin plus bevacizumab compared
with 14.6 months with 5-FU/leucovorin or iri-
notecan (p = 0.008).[8] In a pivotal study, the ad-
dition of bevacizumab to irinotecan as first-line
therapy for metastatic colorectal cancer was
associated with a significant increase in median
overall survival, progression-free survival, and
duration of response (figure 2).[7] In the BICC-C
study, patients receiving FOLFIRI, modified iri-
notecan, or capecitabine plus irinotecan experi-
enced median overall survival of 23.1, 17.6, and
18.9 months, respectively. A protocol change al-
lowed for the addition of bevacizumab mid-trial,
and in patients receiving this drug, median over-
all survival was not reached with FOLFIRI plus
bevacizumab, but was reached at 19.2 months
with modified irinotecan plus bevacizumab. No
direct comparisons between regimens with or with-
out bevacizumabweremade.[41]When bevacizumab
was added to oxaliplatin-containing chemotherapy
regimens, a significant improvement in progression-
free survival (9.4 vs 8.0 months; p= 0.0023), but
not overall survival (21.3 vs 19.9months; p= 0.077),
was seen.[42] As second-line therapy in patients
who had progressed on a non-bevacizumab-con-
taining regimen, the addition of bevacizumab
to oxaliplatin plus infusional 5-FU/leucovorin
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(FOLFOX) 4 was associated with a significant
increase in overall survival (12.9 vs 10.8 months;
p= 0.0011).[43]
With respect to adverse events associated with
bevacizumab, the elderly may experience an in-
creased risk of stroke and other arterial events,
and the drug is associated with impaired wound
healing and, rarely, gastrointestinal perforation.[14]
Patients with metastatic colorectal cancer that
have progressed on a bevacizumab-containing
regimen are a challenging proposition for the
oncologist. Current guidelines suggest that these
patients should be treated with an anti-EGFR
monoclonal antibody; however, as discussed in
section 2, these agents are only effective in
patients with wild-type KRAS.[14] The BOND-2
study was a phase II trial that investigated the
administration of cetuximab and bevacizumab in
patients with irinotecan-refractory colorectal
cancer (n = 43) that were bevacizumab naı¨ve.[44]
Overall survival was 14.5 months in the cetuximab/
bevacizumab/irinotecan group versus 11.4 months
in the cetuximab/bevacizumab group. In addi-
tion, time to tumor progression and response
rates were 7.3 months and 37%, respectively, in
the cetuximab/bevacizumab/irinotecan groups ver-
sus 4.9 months and 20% in patients who received
cetuximab/bevacizumab. The toxicity profile of
the cetuximab/bevacizumab/irinotecan combina-
tion is comparable with the toxicities seen with
the individual agents.[44] The CAIRO-2 study was
a phase III trial of capecitabine, oxaliplatin plus
bevacizumab, with or without cetuximab.[45] A
significant decrease in progression-free survival
was observed in the cetuximab/bevacizumab
arm versus the control arm (9.8 vs 10.7 months;
p = 0.019). Diarrhea was the most frequent grade
3–4 toxicity, and an increase in skin toxicity
was observed in the cetuximab/bevacizumab
group.[45]
The observational cohort BRiTE study show-
ed that changing the chemotherapy regimen but
continuing bevacizumab therapy after disease
progression was associated with a significantly
greater overall survival than continuing chemo-
therapy without bevacizumab (hazard ratio 0.48;
p < 0.001).[46] While encouraging, these data are
from an observational study and will need to be


























Fig. 2. Median overall survival, progression-free survival, and duration of response in 813 patients with previously untreated metastatic
colorectal cancer treated with irinotecan plus bolus fluorouracil/leucovorin (IFL) and randomized to treatment with bevacizumab or placebo in
a multicenter controlled study.[7] * p <0.001.
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5. Surgical Resection of Metastatic
Disease and Perioperative
Chemotherapy
Surgical resection offers the chance of long-term
survival in patients who present with colorectal
cancer and hepatic or pulmonary metastases,
with a 25–35% rate of 5-year survival observed
after complete resection.[47] Important aspects
of patient selection for surgical resection include
the likelihood of achieving negative surgical
margins and the maintenance of adequate liver
reserve.[14] The aim of surgical resection in this
setting is curative, and the procedure should only
be considered in patients in whom complete re-
moval of known tumors is deemed possible.[14]
European guidelines recommend the use of peri-
operative chemotherapy in patients with resect-
able liver metastases, administered for 3 months
before and 3 months after surgery.[47] The use of
perioperative FOLFOX4 improved 3-year pro-
gression-free survival by 7.3% in all randomized
patients and by 9.2% in all patients undergoing
resection in the European Organization for Re-
search and Treatment of Cancer Intergroup trial
40983.[48]
Initially, unresectable metastases may be ren-
dered resectable following the administration of
systemic chemotherapy with or without proce-
dures of liver hypertrophy or embolization. Use
of first-line combination chemotherapy in this
setting has been shown to allow resection rates of
up to 40% in patients who were not previously
eligible for surgery.[49] As discussed in section 4,
the addition of bevacizumab to combination
chemotherapy improves outcomes in patients
with metastatic disease, and the use of this strat-
egy prior to metastasectomy has increased. The
safety of preoperative chemotherapy on surgical
outcomes has been a matter of some concern,
particularly with regard to wound-healing com-
plications following preoperative bevacizumab
therapy. However, a number of recent studies
have shown that secondary resection following
bevacizumab therapy is feasible, safe, and ef-
fective.[50-53] A nonrandomized study in which
56 patients with potentially curable metastatic
colorectal cancer received preoperative treatment
with capecitabine/oxaliplatin (XELOX) plus bev-
acizumab for six cycles with bevacizumab omitted
for the final cycle showed no increases in the rate
of surgical or wound-healing complications or
bleeding severity with this regimen.[51] Further-
more, neoadjuvant bevacizumab did not affect
liver regeneration after resection.[51] In the First
BEAT, 225 of 1965 patients underwent curative
hepatic metastasectomy, of whom complete re-
section with no residual disease was achieved in
173 patients.[52] First BEAT collected safety data
(primary endpoint) prospectively from patients
undergoing surgery and hence, is the largest set of
data using targeted therapy in this population.
Patients in this study received fluoropyrimidine-
based chemotherapy plus bevacizumab, with
bevacizumab therapy ceasing a median of 64 days
before surgery. A 2-year overall survival rate of
89% was seen in patients undergoing surgical re-
section with no residual disease.[52] The incidence
of grade 3 or 4 bleeding, wound-healing compli-
cations, and gastrointestinal perforation were
2.7%, 1.8%, and 2.2%, respectively, with no in-
crease seen compared with historic controls.[52]
In the NO16966 trial (study of Xeloda [cap-
ecitabine] as a first-line therapy in patients with
metastatic colorectal cancer), 1400 patients were
randomized to receive XELOX or FOLFOX4
with or without bevacizumab in a 2 · 2 design.[52]
NO16966 was designed to demonstrate the non-
inferiority of XELOX to FOLFOX4, and the
data were collected retrospectively. Curative re-
section was performed in 44 patients randomized
to bevacizumab and 34 patients receiving chemo-
therapy plus placebo. Two-year overall survival
was 90.9% in bevacizumab recipients compared
with 82.3% in those receiving placebo, but, more
importantly, no increased incidence of bleeding,
wound-healing complications, or gastrointestinal
perforation was seen in bevacizumab recipients.[52]
In a study that included 219 patients, the addition
of bevacizumab to FOLFOX as preoperative
chemotherapy in patients undergoing hepatic
resection produced a significant increase in res-
ponse compared with FOLFOX alone.[53] A
major or complete pathologic response in patients
receiving between one and eight cycles of chemo-
therapy occurred in 67% of patients receiving
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FOLFOX plus bevacizumab compared with 48%
of FOLFOX recipients (p = 0.00017). A longer
duration of preoperative chemotherapy was asso-
ciated with a higher incidence of postoperative
sinusoidal injury and liver insufficiency.[53]
6. New Treatment Paradigms in
Colorectal Cancer
The improvements in survival seen with the
increased number of chemotherapeutic agents
and the expanded ways in which these agents are
used have brought about a changing paradigm
for the treatment of colorectal cancer (figure 3).
In the past, metastatic colorectal cancer was treated
with first-line therapy until progression, at which
point treatment was switched to a regimen active
in the second-line setting. This pattern was con-
tinued until patients had received all five active
classes of drug, after which they were enrolled in
clinical trials. The new approach to treatment
views the choice of first and subsequent lines of
treatment as a continuum rather than isolated
choices. A patient’s treatment may be changed
prior to disease progression. Alternately, treat-
ment may consist of aggressive treatment periods
followed by breaks or maintenance therapy fol-
lowing treatment response. This approach to
treatment may minimize the toxicity seen with
individual agents.[54] For example, oxaliplatin is
associated with both acute and delayed sensory
neuropathy, and a large proportion of patients
receiving cumulative doses of oxaliplatin de-
velop grade 3 cumulative neurotoxicity that may
take several months to resolve.[54] A balance be-























































Fig. 3. Suggested treatment continuums for metastatic colorectal cancer using (a) intensive or (b) less intensive therapy.[54]
5-FU = fluorouracil; FOLFIRI = irinotecan plus infusional fluorouracil/leucovorin; FOLFOX =oxaliplatin plus infusional fluorouracil/leucovorin;
LV = leucovorin. * indicates that cetuximabmay be administered alone for patients intolerant to irinotecan. Reproduced fromGoldberg et al.,[54]
copyright 2007, with permission of AlphaMed Press, Inc.
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OPTIMOX 1 and 2 trials. In the OPTIMOX 1
trial, patients were randomized to FOLFOX4
every 2 weeks until disease progression or high-
dose FOLFOX7 for six cycles followed by 5-FU/
leucovorin for 12 cycles, after which they re-
started FOLFOX7.[55] Disease duration and
overall survival was similar in each group, but pa-
tients receiving FOLFOX7 had a greatly reduced
incidence of peripheral neuropathy, particularly
during the later stages of treatment. To refine
these data, the OPTIMOX 2 study randomized
patients to six cycles of modified FOLFOX7 fol-
lowed by 5-FU/leucovorin maintenance until
progression, or six cycles of modified FOLFOX7
followed by cessation of therapy until tumor pro-
gression; in both groups, modified FOLFOX7
was reintroduced at disease progression.[56] The
duration of disease control and progression-free
survival was significantly higher in patients re-
ceiving maintenance therapy, but the overall
survival was similar in both groups. Therefore,
although the authors of OPTIMOX 2 concluded
that chemotherapy discontinuation could be
safely considered in selected patients, these re-
sults suggest maintenance therapy in metastatic
colorectal cancer is important, although its role is
not yet clearly defined. As a final note on the fu-
ture treatment of colorectal cancer, the cytostatic
mechanism of action and relatively low toxicity
make bevacizumab a suitable agent for use as
maintenance therapy in colorectal cancer, as it is
in non-small-cell lung cancer. An ongoing, ran-
domized, phase III study investigating this use is
currently ongoing and results are eagerly awaited
to further help guide the use of bevacizumab in
these patients.
7. Conclusions
In contrast to 15 years ago, the oncologist is
faced with a choice of treatments for patients
with metastatic colorectal cancer and is able to
predict survival of almost 2 years in these patients.
Treatment should be tailored to the individual by
using prognostic and predictive factors, including
biomarkers. The use of these biomarkers can al-
ready assist with personalized treatment plans by,
for example, identifying patients whose tumors
will not respond to EGFR inhibitors, and this
approach to patient care is anticipated to grow
markedly in the future. Much work has been
undertaken to investigate and better understand
the tumor environment. The addition to chemo-
therapy of biologic agents such as bevacizumab
that target angiogenesis, significantly improves
the survival of patients with metastatic colorectal
cancer independently of its biomarker status.
Improved surgical techniques and use of chemo-
therapy plus biologic agents has also improved
the odds of curative resection in patients with
hepatic metastases. The prolonged survival seen
with these advances in therapy has raised ques-
tions about adverse events seen with cumulative
doses of chemotherapy agents and brought about
new treatment paradigms, including the use of
periods of intensive chemotherapy followed by
drug holidays, and changing therapy early to avoid
cumulative toxicity. These advances provide the
platform to enable a personalized care plan for-
mulated on an individual patient basis to further
improve outcomes in metastatic colorectal cancer.
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